Efficacy of ceftobiprole in a murine model of bacteremia and disseminated infection
Journal of Medical Microbiology · 2023
DOI: 10.1099/jmm.0.001755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2023. Verfasst von Charlotte Cumper und 4 weiteren Autor:innen. Beteiligte Einrichtung: Charles River Laboratories, Portishead, UK. Hauptthemen laut MEDLINE: Staphylococcal Infections, Bacteremia, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Introduction
Ceftobiprole is an advanced-generation broad-spectrum parenteral cephalosporin with activity against MSSA and MRSA. Gap Statement. Ceftobiprole is not currently approved for use to treat S. aureus bacteremia and phase three clinical trials are taking place. Drug approval requires further pre-clinical evidence to support this new indication.
Aim
The aim of this study was to evaluate the efficacy of ceftobiprole at the human equivalent efficacious exposure (considering a 500 mg q8h dosing regimen infused over 2 h) against MSSA and MRSA strains in a neutropenic murine model of bacteremia and disseminated infection. Methodology. Two bioluminescent-tagged strains (one MSSA and one MRSA strain) were selected based on their in vitro susceptibility and in vivo growth profiles. Bacterial c.f.u. counts in the blood, lung, kidney, and liver were determined 48 h post-infection or after death. The bioluminescent-tag allowed the visualization of the real-time effects of ceftobiprole therapy compared to the natural progression of the infection in untreated controls.
Results
Treatment with ceftobiprole resulted in a significant reduction of the bacterial load with the bioluminescence reduced by 2-log units and bacterial c.f.u. counts reduced by 3- to 6-log units, depending on the organ and bacterial strain. Survival was 100 % in the ceftobiprole-treated group compared to only 0–20 % survival in the untreated control animals for both strains tested.
Conclusion
These results suggest that treatment with ceftobiprole using a 500 mg q8h dosing regimen studied in several successful phase three trials, has potential as an antibiotic therapy to treat bacteremia and associated disseminated infections caused by either methicillin-susceptible or methicillin-resistant strains of S. aureus .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Charles River Laboratories, Portishead, UK.
- Basilea Pharmaceutica International Ltd, Allschwil, Swaziland.
Förderung
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Cumper, C., Richards, C., Smart, J., Litherland, K., & Jones, M. (2023). Efficacy of ceftobiprole in a murine model of bacteremia and disseminated infection. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001755
Vancouver
Cumper C, Richards C, Smart J, Litherland K, Jones M. Efficacy of ceftobiprole in a murine model of bacteremia and disseminated infection. Journal of Medical Microbiology. 2023. doi:10.1099/jmm.0.001755
BibTeX
@article{Cumper2023,
author = {Cumper, Charlotte and Richards, Claire and Smart, Jennifer and Litherland, Karine and Jones, Mark},
title = {Efficacy of ceftobiprole in a murine model of bacteremia and disseminated infection},
journal = {Journal of Medical Microbiology},
year = {2023},
doi = {10.1099/jmm.0.001755}
}
EUVIMED